TY - JOUR
T1 - Treatment effects of methylphenidate on behavioral adjustment in children with mental retardation and ADHD
AU - Pearson, Deborah A.
AU - Santos, Cynthia W.
AU - Roache, John D.
AU - Casat, Charles D.
AU - Loveland, Katherine A.
AU - Lachar, David
AU - Lane, David M.
AU - Faria, Laura P.
AU - Cleveland, Lynne A.
PY - 2003/2
Y1 - 2003/2
N2 - Objective: The effects of stimulant medication treatment were investigated in children with mental retardation (MR) and attention-deficit/hyperactivity disorder (ADHD). Method: Parent and teacher behavioral ratings and reports of side effects were obtained for children (N = 24, mean age = 10.9 years, SD = 2.4) during a placebo-controlled, double-blind, crossover treatment trial with 0.15 mg/kg, 0.30 mg/kg, and 0.60 mg/kg b.i.d- dosages of methylphenidate. Results: The most significant improvements occurred at the 0.60 mg/kg methylphenidate dose for teacher ratings of inattention (p = .024), hyperactivity (p < .001), aggression (p < .001), and asocial behavior (p = .009). No significant improvements, relative to placebo, occurred at the 0.15 mg/kg dosage. Of interest, nearly all significant medication-related behavioral improvements were detected by teachers. However, parents were sensitive raters of side effects, noting more sleeping problems and loss of appetite at the 0.60 mg/kg dose compared with placebo. Conclusions: These results suggest that symptoms of ADHD can be treated successfully in children with ADHD/MR, and consistent with MTA study results, higher doses were most effective. Furthermore, these improvements were not accompanied by increases in symptoms such as staring, social withdrawal, or anxiety.
AB - Objective: The effects of stimulant medication treatment were investigated in children with mental retardation (MR) and attention-deficit/hyperactivity disorder (ADHD). Method: Parent and teacher behavioral ratings and reports of side effects were obtained for children (N = 24, mean age = 10.9 years, SD = 2.4) during a placebo-controlled, double-blind, crossover treatment trial with 0.15 mg/kg, 0.30 mg/kg, and 0.60 mg/kg b.i.d- dosages of methylphenidate. Results: The most significant improvements occurred at the 0.60 mg/kg methylphenidate dose for teacher ratings of inattention (p = .024), hyperactivity (p < .001), aggression (p < .001), and asocial behavior (p = .009). No significant improvements, relative to placebo, occurred at the 0.15 mg/kg dosage. Of interest, nearly all significant medication-related behavioral improvements were detected by teachers. However, parents were sensitive raters of side effects, noting more sleeping problems and loss of appetite at the 0.60 mg/kg dose compared with placebo. Conclusions: These results suggest that symptoms of ADHD can be treated successfully in children with ADHD/MR, and consistent with MTA study results, higher doses were most effective. Furthermore, these improvements were not accompanied by increases in symptoms such as staring, social withdrawal, or anxiety.
KW - Attention-deficit/hyperactivity disorder
KW - Behavior
KW - Mental retardation
KW - Methylphenidate
UR - http://www.scopus.com/inward/record.url?scp=0037317720&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037317720&partnerID=8YFLogxK
U2 - 10.1097/00004583-200302000-00015
DO - 10.1097/00004583-200302000-00015
M3 - Article
C2 - 12544181
AN - SCOPUS:0037317720
SN - 0890-8567
VL - 42
SP - 209
EP - 216
JO - Journal of the American Academy of Child and Adolescent Psychiatry
JF - Journal of the American Academy of Child and Adolescent Psychiatry
IS - 2
ER -